Literature DB >> 8392955

Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma.

N Nagasue1, M Uchida, Y Makino, Y Takemoto, A Yamanoi, T Hayashi, Y C Chang, H Kohno, T Nakamura, H Yukaya.   

Abstract

BACKGROUND: The long-term survival rate after liver resection of hepatocellular carcinoma (HCC) is far from satisfactory, mainly because of high intrahepatic recurrence (IHR) rates. This study was aimed to clarify clinicopathologic factors relevant to IHR after resection of HCC.
METHODS: The 10-year cumulative intrahepatic recurrence rates were analyzed in terms of seven clinical and eight pathological factors in 201 patients with curative hepatic resection.
RESULTS: IHR was found in 121 patients during the follow-up period. The overall IHR rates were 22% at 1 year, 43% at 2 years, 62% at 3 years, 72% at 4 years, 75% at 5 years, and 75% at 10 years. Age, sex, and serum alpha-fetoprotein level, hepatitis B virus markers, and extent of liver resection were not significantly related to the IHR rate. Postoperative chemotherapy mainly with anthracycline tended to suppress IHR (P = 0.0889), but preoperative chemoembolization did not affect IHR. The presence of cirrhosis, satellite nodules, and venous invasion and the absence of capsule formation were associated with higher recurrence rates throughout the observation. Positive surgical margin (< or = 5 mm) was also associated with a higher IHR rate. Although not significant, well-differentiated HCCs showed a higher recurrence rate in comparison with poorly differentiated tumors. Size and number of tumor did not influence the IHR rate.
CONCLUSIONS: Accurate patient selection and adequate hepatic reserve are important considerations in the management of HCC by resection.

Entities:  

Mesh:

Year:  1993        PMID: 8392955     DOI: 10.1016/0016-5085(93)90724-q

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  93 in total

1.  Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B.

Authors:  Shoji Kubo; Kazuhiro Hirohashi; Osamu Yamazaki; Mitsuharu Matsuyama; Hiromu Tanaka; Katsuhiko Horii; Taichi Shuto; Takatsugu Yamamoto; Shuichi Kawai; Kenichi Wakasa; Shuhei Nishiguchi; Hiroaki Kinoshita
Journal:  World J Surg       Date:  2002-02-19       Impact factor: 3.352

2.  Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin.

Authors:  Ming Shi; Chang-Qing Zhang; Ya-Qi Zhang; Xiao-Man Liang; Jin-Qing Li
Journal:  World J Surg       Date:  2004-03-17       Impact factor: 3.352

3.  Microvascular invasion in hepatocellular carcinoma.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Deniz Akata; Mustafa Nasuh Özmen; Muşturay Karçaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

4.  Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies.

Authors:  Alfonso Reginelli; Angelo Vanzulli; Cristiano Sgrazzutti; Luca Caschera; Nicola Serra; Antonio Raucci; Fabrizio Urraro; Salvatore Cappabianca
Journal:  Med Oncol       Date:  2017-04-12       Impact factor: 3.064

5.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

Review 6.  Hepatocellular carcinoma: is current therapy really altering outcome?

Authors:  P J Johnson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

7.  Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.

Authors:  Yonson Ku; Takeshi Iwasaki; Masahiro Tominaga; Takumi Fukumoto; Tetsuya Takahashi; Masahiro Kido; Satoshi Ogata; Masanori Takahashi; Yoshikazu Kuroda; Shinichi Matsumoto; Hidefumi Obara
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

8.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

9.  Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Soo Cheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

10.  Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy.

Authors:  Xiao-Ming Wang; Zhen-Yu Yin; Ren-Xiang Yu; You-Yuan Peng; Ping-Guo Liu; Guo-Yang Wu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.